Mean plasma HDL-C (mg/dL) in 3 groups of patients (CTEPH, PAH and control group).

<p>HDL-C in CTEPH patients is lower compared to control subjects and higher compared to PAH patients. (Mean± SD): CTEPH: (44.7 ± 15.5 mg/dL); PAH: (35.2±11.5 mg/dL); Control: (52.9 ±19.7 mg/dL); p < 0.0001 for the ANOVA test that was performed to compare mean HDL-C among the three groups of patients. P values for post hoc pairwise comparisons were: CTEPH vs PAH: <0.001, CTEPH vs control: <0.001, PAH vs control: <0.001. Circle symbol represents outliers, diamond symbol represents mean HDL-C values, error bars showing SD of the mean.</p

Baseline characteristics for the group of patients with CTEPH.

<p>Baseline characteristics for the group of patients with CTEPH.</p

Association between plasma HDL-C (mg/dL) and absolute change in pulmonary vascular resistance (PVR) post pulmonary thromboendarterectomy (PTE).

<p>Higher baseline HDL-C was associated with a larger decrease in PVR post PTE (r = 0.37, p = 0.049).</p

Association between plasma HDL-C (mg/dL) and presence of right ventricular dilation on echocardiography.

<p>Univariate logistic regression was performed to assess association. Higher plasma HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). Diamond symbol represents mean HDL-C values.</p

Correlation between plasma HDL-C levels and markers of disease severity in patients with CTEPH.

<p>Pearson Correlation Coefficients and P values are shown.</p

Patients’ baseline characteristics and HDL-C levels in the 3 group of patients: CTEPH patients, pulmonary arterial hypertension (PAH) patients and control subjects.

<p>Patients’ baseline characteristics and HDL-C levels in the 3 group of patients: CTEPH patients, pulmonary arterial hypertension (PAH) patients and control subjects.</p